# A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

> **NCT00622713** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 228 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rivastigmine transdermal patch

## Key facts

- **NCT ID:** NCT00622713
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2011-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622713, "A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00622713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*